News & Events
Sunshine Heart - $1.75 million Placement completed, $8.1 million Rights Issue announced
10 / 08 / 2009
Sunshine Heart, Inc. (ASX: SHC) is pleased to announce the successful completion of a private placement to sophisticated and institutional investors in Australia to raise $1.75 million, being 15% of issued capital and the maximum amount which could be raised by the company through the placement without shareholder approval...
Xenome and Axxam initiate discovery partnership focused on novel peptides against GPCR targets
05 / 08 / 2009
Xenome Limited (??Xenome?) today announced it has executed a research collaboration agreement with Axxam SpA (??Axxam?), a leading biotechnology research organization offering early-stage discovery research services for the life science industry....
Sunshine Heart - C-Pulse US Clinical Update
27 / 07 / 2009
Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announced today that the first two patients implanted with the C-Pulse device in April 2009 at The Ohio State University Medical Center in Columbus, Ohio have successfully completed their 3 month follow-up evaluation....
Peplin Initiates its Final Phase 3 Clinical Trial for PEP005 Gel in AK
23 / 07 / 2009
Peplin, Inc. (ASX:PLI) today announced the initiation of its second non-head Phase 3 clinical trial to confirm the efficacy and safety of PEP005 (ingenol mebutate) gel for the treatment of actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, when applied to non-head locations, which include the trunk and extremities...
Novasys Medical Receives $18.95 Million in Second Tranche of Series D Financing
21 / 07 / 2009
Novasys Medical, Inc., developer of the Renessa® treatment for female stress urinary incontinence, announced today that it has received $18.95 million in the second tranche of its previously announced Series D preferred stock financing. The Company received the first tranche of the Series D round in May 2008, with lead investor Versant Ventures and new investors ThreeArch Partners and Skyline Ventures. All three participated in the second tranche, with existing investors Alloy Ventures, Delphi Ventures, GBS Venture Partners and Hercules Technology Growth Capital.
ChemGenex Appoints Mr. Thomas DeZao as Senior Vice President and
20 / 07 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that it has appointed Mr. Thomas DeZao to the position of Senior Vice President and Chief Commercial Officer. Mr. DeZao will commence his position immediately and will lead the company??s commercial efforts including sales, marketing and the coordination of manufacturing activities for the launch of omacetaxine in the USA...
NUON THERAPEUTICS INC. APPOINTS PAULETTE DILLON, CHIEF BUSINESS OFFICER, AND TITO SERAFINI, CHIEF SCIENTIFIC OFFICER
09 / 07 / 2009
Nuon Therapeutics, Inc., a clinical stage, privately-held biopharmaceutical company focused on novel therapies for autoimmune and inflammatory diseases, today announced the appointments of Paulette Dillon to the position of chief business officer and Tito Serafini, Ph.D., to the position of chief scientific officer, both reporting to president and CEO Rodney Pearlman, Ph.D...
Nuon - AFFYMAX CEO ARLENE MORRIS JOINS NUON THERAPEUTICS?? BOARD OF DIRECTORS AS CHAIRPERSON
09 / 07 / 2009
Nuon Therapeutics, Inc., a clinical stage, privately-held biopharmaceutical company focused on novel therapies for autoimmune and inflammatory diseases, announced today that Arlene Morris, president and CEO of Affymax, Inc. (Nasdaq: AFFY), has been elected chairperson of the company??s Board of Directors. A proven commercial leader in the biotechnology and pharmaceutical industry with more than 25 years of experience, Ms. Morris is well suited to work with the management team at Nuon Therapeutics....
ChemGenex to Seek Voluntary De-listing from NASDAQ and to Restructure Board to
29 / 06 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) advises that a decision has been taken by the Board to seek a voluntary de-listing from the NASDAQ Capital Market (??NASDAQ?) and to fully deregister from the U.S. Securities and Exchange Commission??s (??SEC?) ongoing reporting obligations....
ChemGenex??s Omacetaxine Kills Leukemic Stem Cells in Human CML Models
09 / 06 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS), announced today that the results of pre-clinical research which demonstrated that omacetaxine kills model human leukemic stem cells were presented as the14th Congress of the European Hematology Association (EHA) in Berlin, Germany on Sunday. Human leukemic stem cells are known to be insensitive to tyrosine kinase inhibitors (TKIs), the drug family currently approved to treat Chronic Myeloid Leukemia (CML). The work was carried out in collaboration with Professor Tessa Holyoake at the University of Glasgow, Scotland, UK....
ChemGenex??s Omacetaxine Shows Activity in Refractory CML
09 / 06 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that positive, updated data from its phase 2/3 clinical trial study of omacetaxine in chronic myeloid leukemia (CML) patients with resistance to multiple tyrosine kinase inhibitors (TKIs) was presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany on Saturday....
Pivotal Study Results: ChemGenex??s Omacetaxine May Provide the First Viable Drug
02 / 06 / 2009
ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML) was the subject of an oral presentation and discussion overnight at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The open label Phase 2/3 study (CGX-635-CML-202) investigated the use of omacetaxine, administered subcutaneously in CML patients who had failed imatinib and who have the highly drug resistant T315I kinase domain mutation....
ChemGenex Rights Issue Fully Subscribed, Further A$1 Million Placement Completed
27 / 05 / 2009
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the completion of its 1 for 14 nonrenounceable rights issue at A$0.43 per share, raising the maximum A$7.4 million. The rights issue was fully subscribed with demand being greater than the 17,122,453 shares available under the rights issue. The company has completed an A$1 million placement (2,325,580 shares at A$0.43 per share) to a small number of institutional investors to partially satisfy the strong demand and reduce the amount of scale-back required for the rights issue top-up facility....
ChemGenex??s Omacetaxine to be Showcased in Three Oral Presentations at EHA
21 / 05 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today that new data from two clinical studies and one pre-clinical study with omacetaxine will be presented at oral sessions during the forthcoming 14th Congress of the European Hematology Association (EHA) in Berlin, Germany....
Data boost for Peplin
19 / 05 / 2009
A treatment for skin ailments, based on a common weed, has moved closer to commercialisation with the release yesterday of trial data on clearing sunspots...
Peplin `positive' on trial of sun spot treatment
19 / 05 / 2009
SKIN treatment specialist Peplin has reported "positive" results from a late-stage clinical trial of its gel to treat pre-cancerous sun spots...
Xenome - Addition to US patent portfolio for Xen2174
23 / 04 / 2009
Xenome Limited ("Xenome") today announced the issuance of US patent 7,507,717 entitled "Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)". This patent adds to the extensive portfolio surrounding chi-conopeptides and analogues, including Xen2174, the?
Hatchtech board and management changes
21 / 04 / 2009
Biotechnology company Hatchtech Pty Ltd today announced that Paul MacLeman has resigned as Chief Executive Officer and Director. The company congratulates Dr MacLeman who is leaving to take up the CEO role at a high profile publicly listed biotechnology company. Since…
Sunshine Heart - First U.S. C-Pulse Implants
20 / 04 / 2009
Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies announced today that The Ohio State University Medical Center in Columbus, Ohio has successfully completed the first two implants of the Company's C-PulseTM heart assist system under a?